Mink Therapeutics Inc (INKT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mink Therapeutics Inc (INKT) has a cash flow conversion efficiency ratio of 148.472x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.08 Billion) by net assets ($-14.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Mink Therapeutics Inc for the company's overall valuation and market capitalisation.
Mink Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mink Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mink Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mink Therapeutics Inc ranked by their cash flow conversion efficiency. See INKT debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunsuria Bhd
KLSE:3743
|
-0.024x |
|
Bonus Biogroup
TA:BONS
|
0.710x |
|
EasyJet PLC
LSE:EZJ
|
0.153x |
|
Thinkific Labs Inc
TO:THNC
|
-0.004x |
|
Talphera Inc.
NASDAQ:TLPH
|
-0.272x |
|
Jade Gas Holdings Ltd
AU:JGH
|
-0.048x |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
-0.037x |
|
HSS Engineers Bhd
KLSE:0185
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Mink Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mink Therapeutics Inc from 2019 to 2025. View Mink Therapeutics Inc (INKT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-14.23 Million | $-5.93 Million | 0.416x | -14.64% |
| 2024-12-31 | $-19.59 Million | $-9.56 Million | 0.488x | -44.12% |
| 2023-12-31 | $-18.06 Million | $-15.76 Million | 0.873x | -98.14% |
| 2022-12-31 | $-401.30K | $-18.87 Million | 47.014x | +8814.55% |
| 2021-12-31 | $23.78 Million | $-12.83 Million | -0.539x | -448.59% |
| 2020-12-31 | $-53.87 Million | $-8.34 Million | 0.155x | -62.37% |
| 2019-12-31 | $-36.33 Million | $-14.94 Million | 0.411x | -- |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more